Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations

Journal of Viral Hepatitis

Volumn 10, Issue 6, 2003, Pages 450-454

  Raptis, I ^a,b   Koskinas, J ^a   Emmanouil, T ^a   Hadziyannis, S ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Hepatitis B virus infection; Hepatitis C virus infection; Hepatocellular carcinoma

Indexed keywords

ADULT; ARTICLE; CHRONIC HEPATITIS; FEMALE; GREECE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEX RATIO;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; GREECE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 0242298691     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00442.x     Document Type: Article

References (48)

1. Di Bisceglie A, Rustgi V, Hoofnagle J, Dusheiko G, Lotze M. Hepatocellular carcinoma. NIH conference. Ann Intern Med 1988; 108: 390-401.
2. Bosch FX. Global epidemiology of hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchil Livingstone, 1997: 13-28.
3. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-963.
4. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-236.
5. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19: 271-285.
6. Schafer D, Sorrell M. Hepatocellular carcinoma. Lancet 1999; 353: 1253-1257.
7. Abeloff M. Hepatocellular carcinoma risk factors. Models with mechanisms of hepatocarcinogenesis. In: Abeloff M. Armitage J, Lichter A, Niederhuber J eds. Clinical Oncology. USA: Churchill Livingstone (Elsevier). 1995: 1306-1311.
8. De Vita VT. Hepatocellular carcinoma, etiologic factors. In: De Vita VT, Hellman S, Rosenberg SA. eds. Cancer: Principles and Practice at Oncology. 4th edn. Athens, Greece: Lipincott Williams and Wilkins. 1993: 885-887.
9. Cancer morbidity in Greece. Greek Cancer Registry. Central Health Council, Ministry of Health and Welfare, Athens, Greece. 1991: 42-43.
10. Hadziyannis S, Tabor E, Kaklamani E et al. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int J Cancer 1995; 60: 627-631.
11. Zavitsanos X, Hatzakis A, Kaklamani E et al. Association between hepatitis C virus and hepatocellular carcinoma using assays based on structural and nonstructural hepatitis C virus peptides. Cancer Res 1992; 52: 5364-5367.
12. Kuper HE, Tzonou A, Kaklamani E et al. Hepatitis B and C viruses in the etiology of hepatocellular carcinoma: a study in Greece using third-generation assays. Cancer Causes Control 2000; 11: 171-175.
13. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet 1981; 2: 1129-1233.
14. Kew MC, Yu MC, Kedda MA, Coppin A, Sarkin A, Hodgkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in Southern African Blacks. Gastroenterology 1997; 112: 184-187.
15. Brechot C. Jaffredo F, Lagorce D et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998; 29: 173-183.
16. Kew M. Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Viral Hepat Rev 1998; 4: 259-269.
17. Harrison T. Viral hepatitis and primary liver cancer. In: Arrand JR, Harper DR, eds. Viruses and Human Cancer. Oxford: BIOS Scientific Publishers Ltd, 2000: 17-38.
18. Martin P. Hepatocellular carcinoma: risk factors and natural history. Liver Transplant Surg 1998; 4: S87-S91.
19. Kubicka S, Rudolph KL, Hanke M et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20: 312-318.
20. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C. Ferenci P, Gangi A. Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol 2000; 12: 941-948.
21. Van Roey G, Fevery J, Van Steenbergen W. Hepatocellular carcinoma in Belgium: clinical and virological characteristics of 154 consecutive cirrhotic and non-cirrhotic patients. Eur J Gastroenterol Hepatol 2000; 12: 61-66.
22. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32: 225-237.
23. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998; 45: 1206-1213.
24. Bruix J, Calvet X, Costa J et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-1006.
25. Haydon GH, Jarvis LM, Simmonds P, Harrison DJ, Garden OJ, Hayes PC. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut 1997; 40: 128-132.
26. Trichopoulos D, Gerety RJ, Sparos L et al. Hepatitis B and primary hepatocellular carcinoma in a European population. Lancet 1978; 2: 1217-1219.
27. Stamouli M, Gizaris V, Totos G, Papaevangelou G. Decline of hepatitis B infection in Greece. Eur J Epidemiol 1999; 15: 447-449.
28. Papaevangelou G. Hepatitis B immunization program: lessons learnt in Greece vaccine. Vaccine 1998; 16: S45-S47.
29. Hadziyannis S, Gianoulis G, Hadziyannis E et al. Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. J Hepatol 1993; 17: S72-S77.
30. Manesis E, Hadziyannis S, Karvountzis G, Moussouros A. Merikas G. HBsAg positive and HBsAg negative hepatocellular carcinoma in Greece. 12th Meeting of EASL. Arch Hellenic Med Soc. 1973; 3 (Suppl.): 4-10.
31. Hadziyannis SJ. Detection of HBsAg by passive haemagglutination. Lancet 1974; II: 344-345.
32. Goritsas CP, Athanasiadou A, Arvaniti A, Lampropoulou-Karatza C. The leading role of hepatitis B and C viruses as risk factors for the development of hepatocellular carcinoma. A case control study. J Clin Gastroenterol 1995; 20: 220-224.
33. Kaklamani E, Trichopoulos D, Tzonou A et al. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 1974-1976.
34. Tabor E. Hepatocellular carcinoma: global epidemiology. Dig Liver Dis 2001; 33: 115-117.
35. Stroffolini T, Andreone P, Andriulli A et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998; 29: 944-952.
36. Papadimitropoulos V, Giustozi A, Papaioannou C et al. The prevalence of HCV infection in the general population of different areas of Greece. In: Hadziyannis S, ed. Hepatitis C 1998. Athens: Paschalidis. 1888: 163-170.
37. Lee WM. Hepatitis B virusinfection. NEJM 1997; 337: 1733-1745.
38. Lauer G, Walker B. Hepatitis C virus infection. NEJM 2001; 345: 41-52.
39. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995; 21: 77-82.
40. Hadziyannis S. Hepatitis Be antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7-36.
41. Hadziyannis SJ, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins, 1991: 673-676.
42. Papatheodoridis G, Manesis E, Hadziyannis S. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313.
43. Hadziyannis SJ. Primary liver cancer and its relationship to chronic infection with the hepatitis B virus. Springer Semin Immunopathol 1981; 3: 473-485.
44. Fattovich G, Giustina G, Realdi G, Corrocher G, Schalm SW and the European Concerted Action on Viral Hepatitis (Eurohep). Long term outcome of hepatitis Be antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26: 1338-1342.
45. Fattovich G, Giustina G, Sanchez-Tapias J et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93: 896-900.
46. Fattovich G, Giustina G, Degos F et al. Effectiveness of Interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27: 201-205.
47. Nishiguchi S, Kuroki T, Nakatani S et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
48. Papatheodoridis GV, Ppapadimitropoulos VC, Hadziyannis SJ. Effect of Interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol ther 2001; 15: 689-698.